Vector BioPharma
Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients.
Vector BioPharma has raised €29M across 1 funding round, most recently a Series A round in Aug 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€29M
€29,168,692
Funding rounds
1
Investors
0
distinct backers
Active since
2022-08
latest 2022-08
Funding by year
EUR raised per yearVector BioPharma — funding by year — interactive chart.
Data table
| Vector BioPharma — funding by year | |
|---|---|
| 2022 | €29M |
Signals
Medium confidenceRaise-next likelihood9
base rate 44% for Series A
- ▼ Past typical raise window
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-12 | Series A | €29M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData